Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia (Q34661211)

3 August 2017

1 reference

title

Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia (English)

1 reference

3 August 2017

0 references

0 references

0 references

Meltzer HY

1

1 reference

3 August 2017

publication date

1 January 1989

1 reference

3 August 2017

1 reference

3 August 2017

volume

99 Suppl

1 reference

3 August 2017

page(s)

S18-27

1 reference

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF00442554

Increased brain dopamine and dopamine receptors in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF00442554

Who should receive clozapine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF00442554

Neuromuscular dysfunction in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF00442554

The Effect of Neuroleptics on Serum Prolactin in Schizophrenic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF00442554

The dopamine hypothesis of schizophrenia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF00442554

Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF00442554

Plasma phenylalanine, tyrosine, and tryptophan in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF00442554

Molecular pathology of schizophrenia: more than one disease process?

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Abnormal involuntary movements in schizophrenia: are they related to the disease process or its treatment? Are they associated with changes in dopamine receptors?

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Influence of antipsychotics and serotonin antagonists on presynaptic receptors modulating the release of serotonin in synaptosomes of the nucleus accumbens of rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Glucocorticoid-biogenic amine interactions in relation to mood and behavior

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

New insights into schizophrenia through atypical antipsychotic drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Stimulation of corticosterone and beta-endorphin secretion in the rat by selective 5-HT receptor subtype activation

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Stimulation of serum cortisol and prolactin secretion in humans by MK-212, a centrally active serotonin agonist

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Reduced cataleptogenic effects of some neuroleptics in rats with lesioned midbrain raphe and treated with p-chlorophenylalanine

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Evidence that the stimulus properties of apomorphine are mediated by both D1 and D2 receptor activation

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Increased dopamine-receptor sensitivity in schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

The risks and benefits of clozapine versus chlorpromazine

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

The significance of homovanillic acid and 3,4-dihydroxyphenylacetic acid concentrations in human lumbar cerebrospinal fluid

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Neurotransmitter Receptors in Frontal Cortex of Schizophrenics

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

On the relevance of preferential increases of mesolimbic versus striatal dopamine turnover for the prediction of antipsychotic activity of psychotropic drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Tolerability and therapeutic effect of clozapine. A retrospective investigation of 216 patients treated with clozapine for up to 12 years

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Multiple receptors for dopamine

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Homovanillic acid concentrations in brain, CSF and plasma as indicators of central dopamine function in primates

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Effects of debrisoquin on CSF and plasma HVA concentrations in man.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Positive and negative schizophrenic symptoms and the role of dopamine

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

The current status of the dopamine hypothesis of schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Effect of clozapine on the metabolism of serotonin in rat brain

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Potency of antipsychotics in reversing the effects of a hallucinogenic drug on locus coeruleus neurons correlates with 5-HT2 binding affinity.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Some atypical neuroleptics inhibit [3H]SCH 23390 binding in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Clozapine: neuroleptic-induced EPS and tardive dyskinesia

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Clozapine increases rat serum prolactin levels

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Alterations of cerebrospinal fluid 5-hydroxyindoleacetic acid, and total blood serotonin content during clozapine treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Adrenocortical hormone status affects responses to dopamine receptor agonists

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Plasma drug and homovanillic acid levels in psychotic patients receiving neuroleptics

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Brain Serotonin Content: Physiological Regulation by Plasma Neutral Amino Acids

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Activation of tuberoinfundibular dopamine neurons following the acute administration of atypical antipsychotics

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

The role of serotonin in schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Growth hormone and prolactin response to apomorphine in schizophrenia and the major affective disorders. Relation to duration of illness and depressive symptoms

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Effects of clozapine, thioridazine, perlapine and haloperidol on the metabolism of the biogenic amines in the brain of the rat

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Effect of Clozapine on Apomorphine-Induced Growth Hormone Secretion and Serum Prolactin Concentrations in Schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Serotonergic component of SCH 23390: in vitro and in vivo binding analyses

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Effects of clozapine on the activity of central dopaminergic and noradrenergic neurons

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Antipsychotic efficacy of clozapine in correlation to changes in catecholamine metabolism in man.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Effect of typical and atypical antipsychotic drugs on 5-HT2 receptor density in rat cerebral cortex

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

A mechanism for glucocorticoid toxicity in the hippocampus: increased neuronal vulnerability to metabolic insults.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

D1 dopamine receptor--the search for a function: a critical evaluation of the D1/D2 dopamine receptor classification and its functional implications

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Pharmacology of mesocortical dopamine neurons

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Clozapine--a potential antipsychotic agent without extrapyramidal manifestations.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Basal ganglia and limbic system pathology in schizophrenia. A morphometric study of brain volume and shrinkage

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Tritiated LSD Binding in Frontal Cortex in Schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Effect of clozapine in severe tardive dyskinesia: a case report

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Relation of clinical symptoms to apomorphine-stimulated growth hormone release in mood-incongruent psychotic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Effect of clozapine on human serum prolactin levels

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Preliminary studies of human cortical 5-HT2 receptors and their involvement in schizophrenia and neuroleptic drug action

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Chronic treatment with classical and atypical antipsychotic drugs differentially decreases dopamine release in striatum and nucleus accumbens in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Loxapine and clozapine decrease serotonin (S2) but do not elevate dopamine (D2) receptor numbers in the rat brain

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Biochemical evidence for a transmitter role of dopamine in the rat hippocamus

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Differential Effects of Classical and Atypical Antipsychotic Drugs on A9 and A10 Dopamine Neurons

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

The central action of clozapine

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Effect of clozapine on 5-HIAA excretion in urine and CSF of psychotic patients and on serotonin metabolism in rat brain

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Clozapine blocks disruptive and discriminative stimulus effects of quipazine.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Evidence for different states of the dopamine D1 receptor: clozapine and fluperlapine may preferentially label an adenylate cyclase-coupled state of the D1 receptor

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Interaction of the D1 receptor antagonist SCH 23390 with the central 5-HT system: radioligand binding studies, measurements of biochemical parameters and effects on L-5-HTP syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Clozapine--a serotonin antagonist?

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Effects of clozapine on cerebral catecholaminergic neurone systems

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

3,4-Dihydroxyphenylacetic acid and homovanillic acid in rat plasma: Possible indicators of central dopaminergic activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Effect of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Plasma homovanillic acid as a predictor of response to neuroleptics

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Antagonism of serotonin receptor mediated neuroendocrine and temperature responses by atypical neuroleptics in the rat

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Does dopamine play a role in schizophrenia?

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Dopamine neurochemical profile of atypical antipsychotics resembles that of D-1 antagonists.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2682729

12 December 2020

Identifiers

DOI

10.1007/BF00442554

1 reference

Dimensions Publication ID

3 August 2017

1028852122

0 references

1 reference